Biotech · global
Cancer Evolves. Can Drugs Keep Up? BrYet Is Betting on Tumor Phenotypes
As tumors continually adopt new genetic escape routes, therapies targeting a single mutation often struggle to keep pace; BrYet argues for targeting abnormal phenotypes shared by cancer cells, an approach with scientific appeal that must also undergo more rigorous clinical validation.
The hardest part of cancer treatment is not only finding the first vulnerability to attack, but that tumors can change themselves under treatment pressure. When one signaling pathway is blocked by a drug, the surviving cells may expand again with new mutations, metabolic states, or cellular identities. Fierce Biotech recently reported that the startup BrYet is focusing its R&D on “cancer-specific phenotypes,” seeking to work around the limits of pursuing only a single genetic alteration.
A phenotype refers to the observable state a cell ultimately displays: how it grows, repairs DNA, handles stress, uses nutrients, or interacts with the surrounding microenvironment. Compared with a list of genetic mutations, phenotype is closer to how cancer cells actually live. BrYet’s core argument is that if certain phenotypes are features that cancer cells commonly depend on for survival and that normal cells possess less often, drugs may be able to constrain the tumor’s evolutionary room before it finds its next escape route.
This line of thinking responds to an unease in precision oncology in recent years: genetic stratification has benefited many patients, but it has also repeatedly shown clinicians how quickly resistance can emerge. Targeted therapies against EGFR, ALK, BRAF, and others have all shown that identifying driver mutations can deliver clear efficacy; yet the same cases also remind people that cancer is not a fixed target, but a population of cells reshaped by selective pressure. If treatment targets only one molecular switch, tumors often have a chance to detour through a bypass route.
Phenotype-driven drug development is therefore not just a change in terminology, but a shift in the question from “which mutation can be inhibited” to “which cancer-cell states are indispensable.” This may include approaches such as synthetic lethality, cellular stress responses, chromatin states, or tumor-specific metabolic dependencies; different companies and research teams vary widely in how they pursue them. Based on currently public summaries, BrYet’s specific targets, drug candidates, clinical stage, and validation data have not been fully laid out, so it should not be interpreted as a breakthrough already proven to change treatment outcomes.
The real test will come down to evidence. If a cancer-specific phenotype is to become a developable therapeutic entry point, researchers need to show that it exists in tumors from a sufficient number of patients, can be identified with reliable testing methods, and that harm to normal tissues after inhibition can be controlled. More difficult still, the phenotype itself may change over time, with treatment history, and with the tumor microenvironment; the cellular state detected today may not fully represent the lesion after relapse.
Regulatory and clinical design will also become more complex. Genetic mutations can often be used with companion diagnostics to define enrollment populations. If a phenotype involves multiple biomarkers or functional tests, the testing standards, reproducibility, and clinical feasibility must be clearly explained. For patients, the most important questions remain straightforward: whether a treatment selected in this way can prolong progression-free survival or overall survival, whether the side effects are acceptable, and whether it offers more value than existing therapies or combination therapies.
BrYet’s proposed direction deserves to be taken seriously because it captures a fundamental contradiction in cancer treatment: medicine needs precision, but tumors are fluid. Starting from cancer-specific phenotypes may allow developers to stop chasing only the answers that tumors have already written into their genes, and instead try to understand the current mechanisms by which they maintain a malignant state. However, until more complete peer-reviewed data, clinical results, and diagnostic strategies are made public, this remains an R&D hypothesis with theoretical tension, not a clinical promise.